Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation

Bone Marrow Transplantation

Volumn 23, Issue 12, 1999, Pages 1245-1250

  Piccirillo, N ^a   Sica, S ^a   Laurenti, L ^a   Chiusolo, P ^a   La Barbera, E O ^a   Sora F ^a   Leone, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Autologous peripheral blood progenitor cell transplantation; CD34+ cells; G CSF assay; G CSF support; Haemopoietic recovery

Indexed keywords

ANTIBIOTIC AGENT; CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MALE; NEUTROPHIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE; SEPSIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

EID: 0033516329     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701795     Document Type: Article

References (20)

1. Tarella C, Castellino C, Locatelli F et al. G-CSF administration after peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplant 1998; 21, 401-407.
2. Kodo H, Tajika K, Takahashi S et al. Acceleration of neutrophilic granulocyte recovery after bone marrow transplantation by administration of recombinant human granulocyte colony stimulating factor. Lancet 1988; ii: 38-39.
3. Sheridan WP, Morstyn G, Wolf M et al. Granulocyte-colony stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1988; ii: 891-895.
4. Stahel RA, Jost LM, Cerny T et al. Randomized study of recombinant human granulocyte-colony stimulating factor recovery after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol 1994; 12: 1931-1938.
5. Linch DC, Milligan DW, Winfield DA et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997; 99: 933-938.
6. Spitzer G, Adkins DR, Spencer V et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol 1994; 12: 661-670.
7. Shimazaki C, Oku N, Uchiyama H et al. Effect of granulocyte-colony stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1994; 13: 271-275.
8. Cortelazzo S, Viero P, Bellavita P et al. Granulocyte-colony stimulating factor following peripheral-blood progenitor-cell transplant in non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 935-941.
9. Klumpp TR, Mangan KF, Goldberg SL et al. Granulocyte-colony stimulating factors accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective randomized trial. J Clin Oncol 1995; 13: 1323-1327.
10. Colby C, McAfee SL, Finkelstein DM, Spitzer TR. Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1998; 21: 1005-1010.
11. Taylor KM, Jagannath S, Spitzer G et al. Recombinant human granulocyte-colony stimulating factor hastens granulocyte recovery after high dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease. J Clin Oncol 1989; 7: 1791-1799.
12. Madero L, Muonz A, Diaz de Heredia A et al for the Spanish working party for bone marrow transplantation in children. G-CSF after autologous bone marrow transplantation for malignant diseases in children. Bone Marrow Transplant 1995; 15: 349-351.
13. Soutre E, Quing W, Penelaud PE. Economic analysis of the use of recombinant human granulocyte-colony stimulating factor in autologous bone marrow transplantation. Eur J Cancer 1996; 32A: 1162-1165.
14. Dunlop DJ, Fitzsimons EJ, McMurray A et al. Filgrastim fails to improve haemopoietic reconstitution following myeloablative chemotherapy and peripheral blood stem cell rescue. Br J Cancer 1994; 70: 943-945.
15. Faucher C, Le Corroller AG, Chabannon C et al. Administration of G-CSF can be delayed after transplantation of autologous G-CSF-primed blood stem cells: a randomized study. Bone Marrow Transplant 1996; 17: 533-536.
16. Testa U, Martucci R, Rutella S et al. Autologous stem cell transplantation: release of early and late acting growth factors relates with hematopoietic ablation and recovery. Blood 1994; 84: 3532-3539.
17. Mossad SB, Longworth DL, Goormastic M et al. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996; 18: 265-271.
18. McQuaker IG, Hunter AE, Pacey S et al. Low-dose Filgrastim significantly enhances neutrophil recovery following peripheral-blood stem-cell transplantation in patients with lympho-proliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1997; 15: 451-457.
19. Bolwell BJ, Pholman B, Abdresen S et al. Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial. Bone Marrow Transplant 1998; 21: 369-373.
20. Ojeda E, Garcia-Bustos J, Aguado MJ et al. G-CSF after PBSC transplantation (letter). Br J Haematol 1998; 101: 592-596.